logo

Tonix Pharmaceuticals Holding Corp. (TNXP)



Trade TNXP now with
  Date
  Headline
6/1/2020 7:15:51 AM FDB To Provide Contract Manufacturing And Development Services To Support Tonix's TNX-1800
5/12/2020 7:40:52 AM Tonix Pharma Q1 Loss Available To Common Stockholders $9.0 Mln Or $0.37/Shr Vs Loss Of $6.2 Mln Or $12.76/Shr Last Year
4/24/2020 7:07:35 AM Tonix: 50% Of Total Number Of Participants Randomized In Phase 3 RELIEF Trial
2/28/2020 8:50:54 AM Tonix Pharmaceuticals Prices $16.01 Mln Common Stock Offering
1/24/2020 7:04:08 AM Tonix Pharma Completes Fed-Fasting And Dose Proportionality Study Of TNX-102 SL
12/10/2019 7:10:00 AM Tonix Pharmaceuticals Says First Patient Enrolled In Phase 3 RELIEF Study
11/15/2019 8:33:49 AM Tonix Pharma Prices $9.0 Mln Public Offering
11/4/2019 7:14:33 AM Tonix Pharma Announces 12-Week Primary Endpoint In Currently-Enrolling Phase 3 RECOVERY Study Of Tonmya
9/16/2019 7:22:27 AM Tonix Announces Publication Of Paper On Triple Reuptake Inhibitor TNX-1600
9/4/2019 7:08:13 AM Tonix Pharma Doses Participants In Phase 1 Study Of TNX-601 For Daytime Treatment Of Posttraumatic Stress Disorder
7/16/2019 8:34:22 AM Tonix Pharma Announces Pricing Of Public Offering Of 9 Mln Shares At $0.60/Shr
6/13/2019 7:17:32 AM Tonix Reports Issuance Of Patent In China For Composition Of TNX-102 SL
4/22/2019 7:11:11 AM Tonix Pharma Says That Breakthrough Therapy Designation Remains In Effect For Tonmya For Posttraumatic Stress Disorder